184 related articles for article (PubMed ID: 38540084)
1. Activation of MAP Kinase Pathway by Polyisoprenylated Cysteinyl Amide Inhibitors Causes Apoptosis and Disrupts Breast Cancer Cell Invasion.
Lazarte JMS; Lamango NS
Biomedicines; 2024 Feb; 12(3):. PubMed ID: 38540084
[TBL] [Abstract][Full Text] [Related]
2. Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines.
Tawfeeq N; Lazarte JMS; Jin Y; Gregory MD; Lamango NS
Oncotarget; 2023 Mar; 14():243-257. PubMed ID: 36961909
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Optimization and MAPK Pathway Activation Anticancer Mechanism of Polyisoprenylated Cysteinyl Amide Inhibitors.
Tawfeeq N; Jin Y; Lamango NS
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830912
[TBL] [Abstract][Full Text] [Related]
4. Polyisoprenylated Cysteinyl Amide Inhibitors Deplete K-Ras and Induce Caspase-dependent Apoptosis in Lung Cancer Cells.
Nkembo AT; Amissah F; Ntantie E; Poku RA; Salako OO; Ikpatt OF; Lamango NS
Curr Cancer Drug Targets; 2019; 19(10):838-851. PubMed ID: 30914025
[TBL] [Abstract][Full Text] [Related]
5. Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling.
Lamango NS; Nkembo AT; Ntantie E; Tawfeeq N
Curr Med Chem; 2021; 28(18):3476-3489. PubMed ID: 33176634
[TBL] [Abstract][Full Text] [Related]
6. Polyisoprenylated cysteinyl amide inhibitors induce caspase 3/7- and 8-mediated apoptosis and inhibit migration and invasion of metastatic prostate cancer cells.
Poku RA; Salako OO; Amissah F; Nkembo AT; Ntantie E; Lamango NS
Am J Cancer Res; 2017; 7(7):1515-1527. PubMed ID: 28744401
[TBL] [Abstract][Full Text] [Related]
7. Disruption of actin filaments and suppression of pancreatic cancer cell viability and migration following treatment with polyisoprenylated cysteinyl amides.
Nkembo AT; Salako O; Poku RA; Amissah F; Ntantie E; Flores-Rozas H; Lamango NS
Am J Cancer Res; 2016; 6(11):2532-2546. PubMed ID: 27904769
[TBL] [Abstract][Full Text] [Related]
8. Polyisoprenylated cysteinyl amide inhibitors disrupt actin cytoskeleton organization, induce cell rounding and block migration of non-small cell lung cancer.
Ntantie E; Fletcher J; Amissah F; Salako OO; Nkembo AT; Poku RA; Ikpatt FO; Lamango NS
Oncotarget; 2017 May; 8(19):31726-31744. PubMed ID: 28423648
[TBL] [Abstract][Full Text] [Related]
9. Suppression of focal adhesion formation may account for the suppression of cell migration, invasion and growth of non-small cell lung cancer cells following treatment with polyisoprenylated cysteinyl amide inhibitors.
Ntantie E; Allen MJ; Fletcher J; Nkembo AT; Lamango NS; Ikpatt OF
Oncotarget; 2018 May; 9(40):25781-25795. PubMed ID: 29899821
[TBL] [Abstract][Full Text] [Related]
10. The antiangiogenic effects of polyisoprenylated cysteinyl amide inhibitors in HUVEC, chick embryo and zebrafish is dependent on the polyisoprenyl moiety.
Nkembo AT; Ntantie E; Salako OO; Amissah F; Poku RA; Latinwo LM; Lamango NS
Oncotarget; 2016 Oct; 7(42):68194-68205. PubMed ID: 27626690
[TBL] [Abstract][Full Text] [Related]
11. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
12. The Anticancer Effects of Marine Carotenoid Fucoxanthin through Phosphatidylinositol 3-Kinase (PI3K)-AKT Signaling on Triple-Negative Breast Cancer Cells.
Ahmed SA; Mendonca P; Messeha SS; Oriaku ET; Soliman KFA
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202644
[TBL] [Abstract][Full Text] [Related]
13. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
14. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
16. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
[TBL] [Abstract][Full Text] [Related]
17. Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells.
Adinew GM; Messeha SS; Taka E; Badisa RB; Antonie LM; Soliman KFA
Nutrients; 2022 May; 14(10):. PubMed ID: 35631261
[TBL] [Abstract][Full Text] [Related]
18. Sinomenine restrains breast cancer cells proliferation, migration and invasion via modulation of miR-29/PDCD-4 axis.
Gao G; Liang X; Ma W
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3839-3846. PubMed ID: 31556312
[TBL] [Abstract][Full Text] [Related]
19. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
[TBL] [Abstract][Full Text] [Related]
20. Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer.
Aguilar BJ; Nkembo AT; Duverna R; Poku RA; Amissah F; Ablordeppey SY; Lamango NS
Eur J Med Chem; 2014 Jun; 81():323-33. PubMed ID: 24852279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
